Table 1 Representative antibody-based drugs used for treating hematologic malignancies

mAbs

Rituximab

CD20

B-NHL

Yes

^85,86,87,88

Ofatumumab

CD20

CLL

Yes

⁹⁰

Obinutuzumab

CD20

DLBCL, MCL, FL, CLL

Yes

^{74,92,93,94,95}

Ibritumomab tiuxetan

CD20

B-NHL

Yes

⁸⁹

Veltuzumab

CD20

B-NHL, CLL

No

⁹¹

Ocrelizumab

CD20

FL

No

⁹⁶

Ocaratuzumab

CD20

B-NHL, CLL

No

^97,98,99

Ublituximab

CD20

CLL

No

³⁵⁴

Epratuzumab

CD22

B-NHL

No

¹¹⁴

Tafasitamab

CD19

DLBCL, FL

Yes

^23,352

Inelituzumab

CD19

B-NHL

No

¹¹²

Galiximab

CD80

FL

No

¹¹³

Alemtuzumab

CD52

PTCL, CLL

Yes

^100,101

MDX-060

CD30

HL, ALCL, T-NHL

No

^102,103

Daratumumab

CD38

MM

Yes

^75,76,77,78

Isatuximab

CD38

MM

Yes

^82,83,84

Dacetuzumab

CD40

MM, NHL, DLBCL

No

^104,105,106

Elotuzumab

CS1 (SLAMF7)

MM

Yes

^79,80,81

Milatuzumab

CD74

MM, MCL, FL, CLL

Yes

^{107,108,109,110}

Lintuzumab

CD33

AML

No

²⁵

BI 836858

CD33

AML

No

¹¹¹

bsAbs

Blinatumomab

CD19/CD3

B-ALL, B-NHL, DLBCL

Yes

^124,125,126

AFM11

CD19/CD3

B-ALL

No

¹²⁷

Mosunetuzumab

CD20/CD3

FL

Yes

¹³¹

Glofitamab

CD20/CD3

B-NHL, DLBCL

No

^132,133

Epcoritamab

CD20/CD3

B-NHL, DLBCL/LBCL, FL

No

^134,135

Odronextamab

CD20/CD3

B-NHL, DLBCL

No

¹³⁶

Plamotamab

CD20/CD3

B-NHL, DLBCL

No

^137,138

Teclistamab

BCMA/CD3

MM

Yes

^{150,151,152,153,154}

Linvoseltamab

BCMA/CD3

MM

No

^155,156

Elranatamab

BCMA/CD3

MM

No

^157,158

Alnuctamab

BCMA/CD3

MM

No

¹⁵⁹

AMG420

BCMA/CD3

MM

No

¹⁶²

TNB-383B

BCMA/CD3

MM

No

¹⁶³

AMG701

BCMA/CD3

MM

No

¹⁶⁴

PF-06863135

BCMA/CD3

MM

No

¹⁶⁵

Bi38-3

CD38/CD3

MM

No

¹⁶⁰

AMG424

CD38/CD3

MM

No

¹⁶¹

ISB-1342

CD38/CD3

MM

No

¹⁶⁶

GBR-1342

CD38/CD3

MM

No

¹⁶⁷

Talquetamab

GPRC5D/CD3

MM

No

¹⁶⁸

Cevostamab

FcRH5/CD3

MM

No

¹⁶⁹

Flotetuzumab

CD123/CD3

AML/MDS

No

^142,146

XmAb14045

CD123/CD3

AML

No

¹⁴⁷

AMG330

CD33/CD3

AML

No

¹⁴³

AMV564

CD33/CD3

AML/MDS

No

¹⁴⁴

JNJ-63709178

CD33/CD3

AML

No

¹⁴⁵

MCLA117

CLEC12A/CD3

AML

No

¹⁴⁸

ESK1-BiTE

WT1/CD3

AML

No

¹⁴⁹

AFM26

BCMA/CD16A

MM

No

¹⁷⁵

TandAb

CD30/CD16A

HL

No

¹⁷⁶

CS1-NKG2D biAb

CS1/NKG2D

MM

No

¹⁷⁸

tsAbs

TsAb

CD19/CD22/CD3

B-ALL

No

¹⁷⁷

161533 TriKE

CD16/IL-15/CD33

AML

No

¹⁷⁹

CiTE

CiTE

PD-L1/CD33/CD3

AML

No

⁶¹³

SMITE

SMITE

CD19/CD3 & CD28/PD-L1

CD19-positive lymphoma or leukemia

No

⁶¹⁴

ADC

Inotuzumab ozogamicin

CD22

B-NHL, B-ALL

Yes

^187,188

Moxetumomab pasudotox

CD22

HCL, B-ALL

Yes

^189,190

Pinatuzumab vedotin

CD22

DLBCL, FL

No

¹⁹¹

BL22

CD22

B-ALL, HL

No

^192,193

Polatuzumab vedotin

CD79b

B-NHL, DLBCL, FL

Yes

^191,209,210

Loncastuximab tesirine

CD19

B-NHL, DLBCL

Yes

^203,204

Coltuximab ravtansine

CD19

B-ALL, B-NHL

No

^205,206

Denintuzumab mafodotin

CD19

B-ALL

No

²⁰⁷

Combotox

CD19 and CD22

B-ALL

No

²⁰⁸

Naratuximab emtansine

CD37

B-NHL

No

²¹³

AGS67E

CD37

B-NHL, T-NHL, CLL, AML

No

^214,215

Brentuximab vedotin

CD30

cHL, PTCL, ALCL, CTCL

Yes

^{181,194,195,196,197}

Camidanlumab tesirine

CD25

cHL

No

²²¹

Belantamab mafodotin

BCMA

MM

Yes

²¹¹

HDP-101

BCMA

MM

No

²¹²

Indatuximab ravtansine

CD138

MM

No

²¹⁶

Lorvotuzumab mertansine

CD56

MM

No

²¹⁷

Milatuzumab doxorubicin

CD74

MM

No

²¹⁸

LM-305

GPRC5D

MM

No

²¹⁹

Gemtuzumab ozogamicin

CD33

AML

Yes

¹⁹⁸

Vadastuximab talirine

CD33

AML

No

^199,200

IMGN779

CD33

AML

No

^201,202

Pivekimab sunirine

CD123

AML

No

²²⁰